Clinical Trial Update: Dose Individualization of Pemetrexed - IMPROVE-II [Phase 4]

View source ↗

Summary

Phase 4 trial update on dose individualization of pemetrexed (IMPROVE-II) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Non Small Cell Lung Cancer, Mesothelioma | Phase 4 | Status: TERMINATED